MedPath
FDA Approval

Trazimera

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Pfizer Laboratories Div Pfizer Inc
DUNS: 134489525
Effective Date
February 14, 2022
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL

Manufacturing Establishments4

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Boehringer Ingelheim Pharma GmbH and Co. KG

Pfizer Laboratories Div Pfizer Inc

340700520

Pfizer Ireland Pharmaceuticals

Pfizer Laboratories Div Pfizer Inc

985586408

Pfizer Manufacturing Belgium NV

Pfizer Laboratories Div Pfizer Inc

370156507

Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC

Pfizer Laboratories Div Pfizer Inc

174350868

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Trazimera

Product Details

NDC Product Code
0069-0305
Application Number
BLA761081
Marketing Category
BLA (C73585)
Effective Date
February 14, 2022

Trazimera

Product Details

NDC Product Code
0069-0308
Application Number
BLA761081
Marketing Category
BLA (C73585)
Route of Administration
INTRAVENOUS
Effective Date
February 14, 2022
Code: P188ANX8CKClass: ACTIBQuantity: 150 mg in 7.15 mL
HISTIDINEInactive
Code: 4QD397987EClass: IACTQuantity: 2.8 mg in 7.15 mL
HISTIDINE MONOHYDROCHLORIDE MONOHYDRATEInactive
Code: X573657P6PClass: IACTQuantity: 3.4 mg in 7.15 mL
SUCROSEInactive
Code: C151H8M554Class: IACTQuantity: 138 mg in 7.15 mL
POLYSORBATE 20Inactive
Code: 7T1F30V5YHClass: IACTQuantity: 0.6 mg in 7.15 mL
© Copyright 2025. All Rights Reserved by MedPath